home / stock / stro / stro articles
SOUTH SAN FRANCISCO, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage onco...
PHILADELPHIA, Nov. 11, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Sutro Biopharma, Inc. (NASDAQ:STRO) ("Sutro"...
STAMFORD, Conn., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Abbott Cooper PLLC is investigating Sutro Biopharma, Inc. (NASDAQ:STRO) ("Sutro" or the "Comp...
Oppenheimer initiated coverage on Sutro Biopharma Inc (NASDAQ: STRO), representing around 200% potential upside. The analysts ...
Brunilda Shtylla, Chief Business Officer at Sutro Biopharma (NASDAQ:STRO), reported a large insider sell on August 29, according to a new SEC filin...
SOUTH SAN FRANCISCO, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage onco...
Brunilda Shtylla, Chief Business Officer at Sutro Biopharma (NASDAQ:STRO), reported a large insider sell on August 28, according to a new SEC filin...
News, Short Squeeze, Breakout and More Instantly...
SOUTH SAN FRANCISCO, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the appointment of Barbara Leyman, Ph.D., a...
- Investigational New Drug application for non-small cell lung cancer trial with luvelta cleared by U.S. Food and Drug Administration; Phase 2 on track to begin dosing in the second half of 2024 - - Patient expansion phase well underway in Phase 2 study of luvelta in combination with be...
– Part 2 of REFRαME-O1, the registration-directed study of luvelta for patients with platinum-resistant ovarian cancer (PROC), is open for enrollment – – Planned 50 patients in Dose-Optimization (Part 1) of REFRαME-O1 have been enrolled and are in foll...